2. Search Result
Search Result
Results for "

LacCer

" in MedChemExpress (MCE) Product Catalog:

6

Inhibitors & Agonists

2

Biochemical Assay Reagents

1

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-154921
    Lactosylceramide (bovine buttermilk)

    LacCer (bovine buttermilk)

    		 Reactive Oxygen Species Inflammation/Immunology
    Lactosylceramide (bovine buttermilk) (LacCer (bovine buttermilk)) is a sphingolipid that highly expressed on the plasma membranes of human phagocytes. Lactosylceramide mediates phagocytosis, chemotaxis, and superoxide generation .
    Lactosylceramide (bovine buttermilk)
  • HY-116392F
    D-threo-PDMP hydrochloride

    		Others Cancer
    D-threo-PDMP hydrochloride is a glucosylceramide (GlcCer) synthase inhibitor that inhibits glucosylceramide (GlcCer) and lactosylceramide (LacCer) levels in B16 melanoma cells. D-threo-PDMP hydrochloride lacks reactivity to the other two surface antigens anti-melanoma monoclonal antibodies M562 and M622 and the major histocompatibility antigen anti-H-2KbDb monoclonal antibody, so it is specific for B16 melanoma sex .
    D-threo-PDMP hydrochloride
  • HY-154921A
    Lactosylceramide (porcine RBC)

    LacCer (porcine RBC)

    		 Endogenous Metabolite Inflammation/Immunology
    Lactosylceramide (LacCer) (porcine RBC) is an endogenous bioactive sphingolipid. Lactosylceramide (porcine RBC) plays a pivotal role in mediating innate immune functions .
    Lactosylceramide (porcine RBC)
  • HY-153830
    LacCer (d18:1/16:0)

    C16 Lactosylceramide (d18:1/16:0)

    		 Endogenous Metabolite Neurological Disease Metabolic Disease
    LacCer (d18:1/16:0) (C16 Lactosylceramide (d18:1/16:0)) is an endogenous bioactive sphingolipid that can form membrane microdomains with Lyn kinase and the αi subunits of inhibitory G protein-coupled receptors (GPCRs). The levels of LacCer (d18:1/16:0) are elevated in the plasma of insulin-resistant cattle. In a mouse model of Niemann-Pick type C1 disease (a neurodegenerative cholesterol-sphingolipid lysosomal storage disorder), the expression of LacCer (d18:1/16:0) is also upregulated. LacCer (d18:1/16:0) can be used in research on metabolic diseases and neurodegenerative diseases .
    LacCer (d18:1/16:0)
  • HY-116392A
    (−)-L-threo-PDMP hydrochloride

    		Glucosylceramide Synthase (GCS) Cancer
    (−)-L-threo-PDMP hydrochloride is the hydrochloride form of (−)-L-threo-PDMP. L-threo-PDMP is a glucosylceramide synthase (GCS) inhibitor. L-threo-PDMP stimulates the proliferation of cultured aortic smooth muscle cells, and that increases the level of LacCer in B16 melanoma cells .
    (−)-L-threo-PDMP hydrochloride
  • HY-E70049
    beta-1,4-N-Acetylgalactosaminyltransferase (CgtA)

    GM2/GD2 synthase

    		 Others Neurological Disease
    beta-1,4-N-Acetylgalactosaminyltransferase (CgtA) (GM2/GD2 synthase) is a key enzyme which catalyzes the conversion of GM3, GD3 and lactosylceramide (LacCer) to GM2, GD2 and asialo-GM2 (GA2), respectively. beta-1,4-N-Acetylgalactosaminyltransferase (CgtA) is a key enzyme to control the synthesis of brain-enriched complex gangliosides .
    beta-1,4-N-Acetylgalactosaminyltransferase (CgtA)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: